EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes

Julien Mazieres, Helene Vioix, Boris M Pfeiffer, Rhiannon I Campden, Zhiyuan Chen, Bart Heeg, Alexis B Cortot

Clinical Lung Cancer · 2023

DOI: 10.1016/j.cllc.2023.06.008 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Lung Cancer, 2023. Verfasst von Julien Mazieres und 6 weiteren Autor:innen. Beteiligte Einrichtung: CHU de Toulouse, Université Paul Sabatier, Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Healthcare KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: MET exon 14 (METex14) skipping is a rare oncogenic driver in non-small-cell lung cancer (NSCLC) for which targeted therapy with MET tyrosine kinase inhibitors (TKIs) was recently approved. Given the heterogeneity in published data of METex14 skipping NSCLC, we conducted a systematic literature review to evaluate its frequency, patient characteristics, and outcomes. METHODS: On June 13, 2022 we conducted a systematic literature review of publications and conference abstracts reporting frequency, patient characteristics, or outcomes of patients with METex14 skipping NSCLC. RESULTS: We included 139 studies reporting frequency or patient characteristics (350,997 patients), and 39 studies reporting clinical outcomes (3989 patients). Median METex14 skipping frequency was 2.0% in unselected patients with NSCLC, with minimal geographic variation. Median frequency was 2.4% in adenocarcinoma or nonsquamous subgroups, 12.0% in sarcomatoid, and 1.3% in squamous histology. Patients with METex14 skipping NSCLC were more likely to be elderly, have adenocarcinoma histology; there was no marked sex or smoking status distribution. In first line of treatment, median objective response rate ranged from 50.7% to 68.8% with targeted therapies (both values correspond to MET TKIs), was 33.3% with immunotherapy, and ranged from 23.1% to 27.0% with chemotherapy. CONCLUSIONS: Patients with METex14 skipping are more likely to have certain characteristics, but no patient subgroup can be ruled out; thus, it is crucial to test all patients with NSCLC to identify suitable candidates for MET inhibitor therapy. MET TKIs appeared to result in higher efficacy outcomes, although no direct comparison with chemotherapy or immunotherapy regimens was found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metAgedHumansExonsMutationProtein Kinase Inhibitors

Stichwörter der Autor:innen

CapmatinibTepotinibTyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-met

Autor:innen und Institutionen

  • CHU de Toulouse, Université Paul Sabatier, Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr.
  • The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Ingress Health, A Cytel Company, Rotterdam, The Netherlands.
  • Université Lille, Centre Hospitalier Universitaire de Lille, Centre national de la recherche scientifique, Inserm, Institute Pasteur de Lille, Lille, France.

Förderung

  • Merck Healthcare KGaA

Zitieren

APA

Mazieres, J., Vioix, H., Pfeiffer, B. M., Campden, R. I., Chen, Z., Heeg, B., & Cortot, A. B. (2023). MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.06.008

Vancouver

Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clinical Lung Cancer. 2023. doi:10.1016/j.cllc.2023.06.008

BibTeX
@article{Mazieres2023,
  author = {Mazieres, Julien and Vioix, Helene and Pfeiffer, Boris M and Campden, Rhiannon I and Chen, Zhiyuan and Heeg, Bart and Cortot, Alexis B},
  title = {MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes},
  journal = {Clinical Lung Cancer},
  year = {2023},
  doi = {10.1016/j.cllc.2023.06.008}
}
Kostenlos starten →